Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nanoenzalutamide
- Development stage
- Preclinical
- Lead developer
- Nanoform
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
**Nanoenzalutamide** is a nanotechnology-enhanced formulation of enzalutamide, used for treating prostate cancer. It works by inhibiting androgen receptors, which are involved in the growth and spread of prostate cancer cells. This formulation is designed to improve patient compliance by reducing pill burden and enhancing bioavailability. It is developed using Nanoform's proprietary CESS technology.
- Other names
- nanocrystalline-enabled enzalutamide
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on nanoenzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nanoenzalutamide.